Health Sciences Research Centre, University of Beira Interior, Covilhã, Portugal.
Ther Drug Monit. 2010 Aug;32(4):512-6. doi: 10.1097/FTD.0b013e3181e5c855.
As add-on therapy, phase III clinical trials of eslicarbazepine acetate (ESL) conducted in patients with refractory partial-onset seizures have shown good efficacy, safety, and tolerability, even in patients taking carbamazepine (CBZ) at baseline (approximately 60% of the enrolled patients). Thus, considering the pharmacological disadvantages of CBZ and the similar efficacy spectrum of CBZ and ESL, switching to ESL may be successful in many patients. As ESL is a prodrug almost instantaneously converted to S-licarbazepine (S-Lic; approximately 95%), an interest in therapeutic drug monitoring (TDM) of S-Lic is likely to develop in the future. This study investigated the plasma concentrations of S-Lic and R-licarbazepine (R-Lic) enantiomers in patients under CBZ long-term treatment to assess the potential interference of CBZ or its metabolites in the enantioselective TDM of ESL (using S-Lic concentrations). A chiral high-performance liquid chromatography assay with ultraviolet detection (HPLC-UV) previously developed and validated by our research group was used. Twenty-four patients admitted to the Coimbra University Hospital and supposedly receiving CBZ long-term treatment were identified. Blood samples were collected from patients and serum CBZ concentrations were measured by the usual TDM protocol. Aliquots of plasma from such patients were also submitted to a chiral HPLC-UV analysis. The bioanalytical data indicated that S-Lic and R-Lic were not present at detectable concentrations in plasma samples of the CBZ-treated patients. The chromatograms generated by the analysis of patient plasma samples, when compared with those obtained from blank plasma samples spiked with S-Lic and R-Lic, clearly showed the absence of interferences at the retention times of both Lic enantiomers. These data support the usefulness of the chiral HPLC-UV method used for the enantioselective TDM of ESL (using S-Lic) for programs in which switching from CBZ to ESL is implemented.
作为附加疗法,在难治性部分发作性癫痫患者中进行的艾司利卡西平醋酸盐(ESL)的 III 期临床试验显示出良好的疗效、安全性和耐受性,即使在基线时服用卡马西平(CBZ)的患者中也是如此(约占入组患者的 60%)。因此,考虑到 CBZ 的药理学劣势以及 CBZ 和 ESL 的相似疗效谱,许多患者转向 ESL 可能会成功。由于 ESL 是一种前药,几乎可以立即转化为 S-licarbazepine(S-Lic;约 95%),因此未来可能会对 S-Lic 的治疗药物监测(TDM)产生兴趣。本研究调查了长期接受 CBZ 治疗的患者中 S-Lic 和 R-licarbazepine(R-Lic)对映异构体的血浆浓度,以评估 CBZ 或其代谢物对 ESL(使用 S-Lic 浓度)对映选择性 TDM 的潜在干扰。本研究使用了我们研究小组之前开发和验证的手性高效液相色谱法(HPLC-UV)进行检测。从 Coimbra 大学医院确定了 24 名接受 CBZ 长期治疗的患者。从患者中采集血样,并按照常规 TDM 方案测量血清 CBZ 浓度。还将来自这些患者的等分血浆样品提交给手性 HPLC-UV 分析。生物分析数据表明,在接受 CBZ 治疗的患者的血浆样品中,S-Lic 和 R-Lic 未达到可检测浓度。与用 S-Lic 和 R-Lic 加标空白血浆样品生成的色谱图相比,分析患者血浆样品生成的色谱图清楚地表明,在两个 Lic 对映异构体的保留时间处均不存在干扰。这些数据支持用于 ESL(使用 S-Lic)对映选择性 TDM 的手性 HPLC-UV 方法的有用性,该方法可用于实施从 CBZ 向 ESL 转换的方案。